Clinical trial NCT04788186 - References

Coronary Artery Disease — Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

Citation(s)

•   Allen JE, Knight S, McCubrey RO, Bair T, Muhlestein JB, Goldberger JJ, Anderson JL
  ß-blocker dosage and outcomes after acute coronary syndrome. Am Heart J. 2017 Feb;184:26-36. doi: 10.1016/j.ahj.2016.10.012. Epub 2016 Oct 22.
•   Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators
  ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308(13):1340-9. doi: 10.1001/jama.2012.12559.
•   Björklund E, Nielsen SJ, Hansson EC, Karlsson M, Wallinder A, Martinsson A, Tygesen H, Romlin BS, Malm CJ, Pivodic A, Jeppsson A
  Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry. Eur Heart J. 2020 May 1;41(17):1653-1661. doi: 10.1093/eurheartj/ehz714.
•   Booij HG, Damman K, Warnica JW, Rouleau JL, van Gilst WH, Westenbrink BD
  ß-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. Cardiovasc Drugs Ther. 2015 Jun;29(3):277-85. doi: 10.1007/s10557-015-6600-y.
•   Brinkman W, Herbert MA, O'Brien S, Filardo G, Prince S, Dewey T, Magee M, Ryan W, Mack M
  Preoperative ß-blocker use in coronary artery bypass grafting surgery: national database analysis. JAMA Intern Med. 2014 Aug;174(8):1320-7. doi: 10.1001/jamainternmed.2014.2356.
•   da Graca B, Filardo G, Sass DM, Edgerton JR
  Preoperative ß-Blockers for Isolated Coronary Artery Bypass Graft. Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005027. doi: 10.1161/CIRCOUTCOMES.118.005027. Review.
•   Dondo TB, Hall M, West RM, Jernberg T, Lindahl B, Bueno H, Danchin N, Deanfield JE, Hemingway H, Fox KAA, Timmis AD, Gale CP
  ß-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017 Jun 6;69(22):2710-2720. doi: 10.1016/j.jacc.2017.03.578.
•   Gillis AM, Skanes AC; CCS Atrial Fibrillation Guidelines Committee
  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: implementing GRADE and achieving consensus. Can J Cardiol. 2011 Jan-Feb;27(1):27-30. doi: 10.1016/j.cjca.2010.11.003.
•   Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, Smith SC Jr, Subacius H; OBTAIN Investigators
  Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol. 2015 Sep 29;66(13):1431-41. doi: 10.1016/j.jacc.2015.07.047.
•   Kohsaka S, Miyata H, Motomura N, Imanaka K, Fukuda K, Kyo S, Takamoto S
  Effects of Preoperative ß-Blocker Use on Clinical Outcomes after Coronary Artery Bypass Grafting: A Report from the Japanese Cardiovascular Surgery Database. Anesthesiology. 2016 Jan;124(1):45-55. doi: 10.1097/ALN.0000000000000901.
•   Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG, Mitchell LB, Atzema C, Gladstone D, Sharma M, Verma S, Connolly S, Dorian P, Parkash R, Talajic M, Nattel S, Verma A; CCS Atrial Fibrillation Guidelines Committee
  2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170-1185. doi: 10.1016/j.cjca.2016.07.591. Epub 2016 Sep 6. Review. Erratum in: Can J Cardiol. 2017 Apr;33(4):552-553.
•   Park JJ, Kim SH, Kang SH, Yoon CH, Cho YS, Youn TJ, Chae IH, Choi DJ
  Effect of ß-Blockers Beyond 3 Years After Acute Myocardial Infarction. J Am Heart Assoc. 2018 Mar 3;7(5). pii: e007567. doi: 10.1161/JAHA.117.007567.
•   Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrières J, Juillière Y, Simon T, Danchin N
  ß blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016 Sep 20;354:i4801. doi: 10.1136/bmj.i4801. Erratum in: BMJ. 2016 Oct 17;355:i5602.
•   Rossello X, Pocock SJ, Julian DG
  Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol. 2015 Sep 15;66(11):1273-1285. doi: 10.1016/j.jacc.2015.07.018. Review.
•   Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, Wang TY
  Comparative Effectiveness of ß-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. Circ Cardiovasc Qual Outcomes. 2019 Jul;12(7):e005103. doi: 10.1161/CIRCOUTCOMES.118.005103. Epub 2019 Jul 9.
•   Shavadia JS, Zheng Y, Green JB, Armstrong PW, Westerhout CM, McGuire DK, Cornel JH, Holman RR, Peterson ED
  Associations between ß-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. Am Heart J. 2019 Dec;218:92-99. doi: 10.1016/j.ahj.2019.09.013. Epub 2019 Oct 20.
•   Thaper A, Kulik A
  Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review. Expert Opin Drug Saf. 2018 Aug;17(8):805-813. doi: 10.1080/14740338.2018.1504019. Epub 2018 Jul 27. Review.
•   Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H
  Risk of Cardiovascular Events in Patients With Diabetes Mellitus on ß-Blockers. Hypertension. 2017 Jul;70(1):103-110. doi: 10.1161/HYPERTENSIONAHA.117.09259. Epub 2017 May 30.
•   Vaishnava P, Eagle KA
  Surgery. ß-Blockers--still a trusted ally or time for retirement? Nat Rev Cardiol. 2014 Sep;11(9):502-3. doi: 10.1038/nrcardio.2014.112. Epub 2014 Jul 29.
•   Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, Rao C, Wang W, Sun H, Hu S, Zheng Z
  Efficacy of Long-Term ß-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation. 2015 Jun 23;131(25):2194-201. doi: 10.1161/CIRCULATIONAHA.114.014209. Epub 2015 Apr 23.

BEta Blocker dEprescription Following Coronary Artery Bypass Graft sURGERy: Feasibility and Safety Pilot (BEEFBURGER Trial)

Details for clinical trial NCT04788186